[go: up one dir, main page]

BR9814904A - Polinucleotìdeo isolado que codifica um polipeptìdeo, polipeptìdeo isolado, e, anticorpo. - Google Patents

Polinucleotìdeo isolado que codifica um polipeptìdeo, polipeptìdeo isolado, e, anticorpo.

Info

Publication number
BR9814904A
BR9814904A BR9814904-0A BR9814904A BR9814904A BR 9814904 A BR9814904 A BR 9814904A BR 9814904 A BR9814904 A BR 9814904A BR 9814904 A BR9814904 A BR 9814904A
Authority
BR
Brazil
Prior art keywords
polypeptide
isolated
antibody
polynucleotide encoding
antibodies
Prior art date
Application number
BR9814904-0A
Other languages
English (en)
Inventor
Darrel C Conklin
Betty A Haldeman
Angelica Grossmann
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Publication of BR9814904A publication Critical patent/BR9814904A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Environmental Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Plant Pathology (AREA)
  • Animal Husbandry (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)

Abstract

"POLINUCLEOTìDEO ISOLADO QUE CODIFICA UM POLIPETìDEO, POLIPEPTìDEO ISOLADO, E, ANTICORPO". Um polipeptídeo mamífero semelhante à citosina, denominado Zcyto10, polinucleotídeos codificando o mesmo, anticorpos que se ligam especificamente ao polipeptídeo, e anticorpos anti-idiotípicos que se ligam aos anticorpos. O Zcyto10 é útil para promover a cura de feridas e para estimular a proliferação de plaquetas.
BR9814904-0A 1997-11-26 1998-11-25 Polinucleotìdeo isolado que codifica um polipeptìdeo, polipeptìdeo isolado, e, anticorpo. BR9814904A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97915697A 1997-11-26 1997-11-26
PCT/US1998/025228 WO1999027103A1 (en) 1997-11-26 1998-11-25 Mammalian cytokine-like polypeptide-10

Publications (1)

Publication Number Publication Date
BR9814904A true BR9814904A (pt) 2000-10-03

Family

ID=25526742

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9814904-0A BR9814904A (pt) 1997-11-26 1998-11-25 Polinucleotìdeo isolado que codifica um polipeptìdeo, polipeptìdeo isolado, e, anticorpo.

Country Status (20)

Country Link
EP (3) EP1032671B1 (pt)
JP (2) JP5191619B2 (pt)
KR (1) KR100574387B1 (pt)
CN (2) CN1618969A (pt)
AT (1) ATE269902T1 (pt)
AU (1) AU739420B2 (pt)
BR (1) BR9814904A (pt)
CA (1) CA2312000C (pt)
CZ (1) CZ300849B6 (pt)
DE (1) DE69824755T2 (pt)
DK (1) DK1032671T3 (pt)
EA (2) EA010741B1 (pt)
ES (1) ES2218872T3 (pt)
HU (1) HU227703B1 (pt)
IL (2) IL136076A0 (pt)
NO (2) NO326561B1 (pt)
NZ (1) NZ504751A (pt)
PL (2) PL198687B1 (pt)
UA (2) UA86350C2 (pt)
WO (1) WO1999027103A1 (pt)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5945511A (en) * 1997-02-20 1999-08-31 Zymogenetics, Inc. Class II cytokine receptor
DE60040240D1 (de) 1999-12-23 2008-10-23 Zymogenetics Inc Löslicher interleukin-20 rezeptor
EP1743648B1 (en) 1999-12-23 2010-03-03 ZymoGenetics, Inc. Method for treating inflammation
US6610286B2 (en) 1999-12-23 2003-08-26 Zymogenetics, Inc. Method for treating inflammation using soluble receptors to interleukin-20
WO2002012345A2 (en) 2000-08-08 2002-02-14 Zymogenetics, Inc. Soluble zcytor 11 cytokine receptors
ATE333888T1 (de) 2000-09-15 2006-08-15 Zymogenetics Inc Verwendung eines polypeptids, welches die extrazelluläre domäne von il-20ra und il-20rb enthält, zur behandlung von entzündungen
AU2002220076A1 (en) * 2000-10-20 2002-05-06 Zymogenetics Inc. Secreted alpha-helical cytokine-like protein zlmda24
WO2002058724A2 (en) * 2001-01-26 2002-08-01 Eli Lilly And Company Use of lp82 to treat body weight disorders
CN1503677A (zh) 2001-02-28 2004-06-09 用lp82治疗造血障碍
EP1439850A4 (en) * 2001-10-22 2006-05-03 Lilly Co Eli SOLUBLE PROTEINS THAT RESIST CYTOKIN SIGNAL TRANSFER PATHS
IL161978A0 (en) 2001-12-17 2005-11-20 Zymogenetics Inc Method for treating cervical cancer
KR20110091598A (ko) 2003-03-24 2011-08-11 지모제넥틱스, 인코포레이티드 항-ｉｌ-22ｒａ 항체 및 결합 파트너 및 염증에 있어서의 사용 방법
WO2005014028A1 (en) * 2003-08-08 2005-02-17 Novo Nordisk A/S Interleukin-20 for treating and diagnosing conditions associated with neovascularisation
WO2005052001A2 (en) * 2003-11-21 2005-06-09 Zymogenetics, Inc. Anti-il-20 receptor antibodies and binding partners and methods of using in inflammation
DE602004032379D1 (de) 2003-12-19 2011-06-01 Novo Nordisk As Prozessierung von peptiden und proteinen
ES2397241T3 (es) 2004-01-21 2013-03-05 Novo Nordisk Health Care Ag Conjugación de péptidos mediante transglutaminasa
US7381794B2 (en) 2004-03-08 2008-06-03 Zymogenetics, Inc. Dimeric fusion proteins and materials and methods for producing them
BRPI0516975A (pt) 2004-10-22 2008-09-30 Zymogenetics Inc anticorpo ou seu fragmento de ligação a antìgeno, composição farmacêutica, imunoconjugado, hibridoma, anticorpo monoclonal, e, uso de um anticorpo ou seu fragmento de ligação a antìgeno
JP2008532931A (ja) 2005-02-08 2008-08-21 ザイモジェネティクス， インコーポレイテッド 抗ｉｌ−２０、抗ｉｌ−２２および抗ｉｌ−２２ｒａ抗体ならびに結合パートナー、ならびに炎症における使用法
EP3219812B1 (en) 2008-05-27 2020-09-02 Agilent Technologies, Inc. Hybridization compositions and methods
KR20110039218A (ko) 2008-06-30 2011-04-15 노보 노르디스크 에이/에스 항－인간 인터루킨－２０ 항체
JP5860699B2 (ja) * 2008-10-07 2016-02-16 ナショナル チェン クン ユニバーシティ 骨粗鬆症の治療のためのｉｌ−２０アンタゴニストの使用
US9303287B2 (en) 2009-02-26 2016-04-05 Dako Denmark A/S Compositions and methods for RNA hybridization applications
US8454956B2 (en) 2009-08-31 2013-06-04 National Cheng Kung University Methods for treating rheumatoid arthritis and osteoporosis with anti-IL-20 antibodies
EP2761028A1 (en) 2011-09-30 2014-08-06 Dako Denmark A/S Hybridization compositions and methods using formamide
US11118226B2 (en) 2011-10-21 2021-09-14 Agilent Technologies, Inc. Hybridization compositions and methods
JP5976849B2 (ja) * 2012-03-05 2016-08-24 シージーン アイエヌシー ＰＴＯ切断及び伸長アッセイによるターゲット核酸配列でのヌクレオチド変異検出｛ＤｅｔｅｃｔｉｏｎｏｆＮｕｃｌｅｏｔｉｄｅＶａｒｉａｔｉｏｎｏｎＴａｒｇｅｔＮｕｃｌｅｉｃＡｃｉｄＳｅｑｕｅｎｃｅｂｙＰＴＯＣｌｅａｖａｇｅａｎｄＥｘｔｅｎｓｉｏｎＡｓｓａｙ｝
WO2013164440A1 (en) 2012-05-03 2013-11-07 Novo Nordisk A/S Methods related to treatment of inflammatory diseases and disorders
WO2014015133A1 (en) 2012-07-19 2014-01-23 National Cheng Kung University Treatment of osteoarthritis using il-20 antagonists
US8603470B1 (en) 2012-08-07 2013-12-10 National Cheng Kung University Use of IL-20 antagonists for treating liver diseases
US8852588B2 (en) 2012-08-07 2014-10-07 National Cheng Kung University Treating allergic airway disorders using anti-IL-20 receptor antibodies
WO2017202813A1 (en) 2016-05-24 2017-11-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of pulmonary bacterial infections
CN111108121A (zh) 2017-04-25 2020-05-05 永福生物科技股份有限公司 Il-20拮抗剂治疗眼病的用途
WO2021072392A1 (en) * 2019-10-10 2021-04-15 The Research Foundation For The State University Of New York Analgesic and anesthetic peptides and other agents
CN113248567B (zh) * 2021-02-10 2023-02-03 渤海大学 一种苦味受体阻滞肽及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT963377E (pt) * 1996-08-30 2009-05-11 Human Genome Sciences Inc Interleucina 19
EP1743648B1 (en) * 1999-12-23 2010-03-03 ZymoGenetics, Inc. Method for treating inflammation

Also Published As

Publication number Publication date
ES2218872T3 (es) 2004-11-16
EP1032671B1 (en) 2004-06-23
EP1424393A2 (en) 2004-06-02
DE69824755D1 (de) 2004-07-29
PL340755A1 (en) 2001-02-26
CN1618969A (zh) 2005-05-25
NO329731B1 (no) 2010-12-13
CZ300849B6 (cs) 2009-08-26
JP2010187698A (ja) 2010-09-02
JP2001524313A (ja) 2001-12-04
EA200401501A1 (ru) 2006-02-24
CZ20001910A3 (cs) 2000-11-15
CN1282372A (zh) 2001-01-31
JP5191619B2 (ja) 2013-05-08
DE69824755T2 (de) 2005-08-04
CN1247780C (zh) 2006-03-29
EP1719780A2 (en) 2006-11-08
PL195304B1 (pl) 2007-08-31
JP5331054B2 (ja) 2013-10-30
KR20010032490A (ko) 2001-04-25
AU739420B2 (en) 2001-10-11
WO1999027103A1 (en) 1999-06-03
NO326561B1 (no) 2009-01-12
EA010741B1 (ru) 2008-10-30
NO20002698D0 (no) 2000-05-26
UA73275C2 (en) 2005-07-15
EP1032671A1 (en) 2000-09-06
EA200000565A1 (ru) 2000-12-25
NZ504751A (en) 2001-10-26
HU227703B1 (en) 2011-12-28
EA005581B1 (ru) 2005-04-28
NO20002698L (no) 2000-07-20
IL136076A (en) 2007-12-03
CA2312000A1 (en) 1999-06-03
EP1719780A3 (en) 2006-12-20
CA2312000C (en) 2013-03-26
KR100574387B1 (ko) 2006-04-27
IL136076A0 (en) 2001-05-20
UA86350C2 (en) 2009-04-27
HUP0100436A2 (hu) 2001-06-28
EP1424393A3 (en) 2004-06-09
HUP0100436A3 (en) 2003-08-28
NO20074516L (no) 2000-07-20
PL198687B1 (pl) 2008-07-31
ATE269902T1 (de) 2004-07-15
AU1607799A (en) 1999-06-15
DK1032671T3 (da) 2004-10-11

Similar Documents

Publication Publication Date Title
BR9814904A (pt) Polinucleotìdeo isolado que codifica um polipeptìdeo, polipeptìdeo isolado, e, anticorpo.
DE68914929D1 (de) Emulgierte Zusammensetzung.
FI916128A7 (fi) Ihmisen karsinoomien kanssa reagoivat uudet vasta-aineet
DE69000210D1 (de) Herstellung von olefinen.
DE69515938D1 (de) Reibbelagmaterialien
BR9307766A (pt) Cimento moído com fibra
DK412489D0 (da) Alfa-underenheden af mac-1-leukocytadhaesionsreceptoren
DE68909432D1 (de) Direkte fixierung von geflochtenen strukturen.
DE4431642B4 (de) Reibbelag
BR9006389A (pt) Cimento asfaltico modificado
DE68910665D1 (de) Futterstoff.
DE3668200D1 (de) Pumpbares aufschuettungsmaterial mit hoher festigkeit.
BR8905709A (pt) Composicoes de cimento tixotropicas
DK620589A (da) Polyester egnet til anvendelse som bindefiber eller -filament
DE68901414D1 (de) Kohlenwasserstoff-dehydrierungsreakionen.
TR199600931A2 (tr) Insaat malzemesi karisimi.
DE69104829D1 (de) Herstellung von reibbelägen.
DE68919463D1 (de) Bremsbackenführungselement und dieses verwendende Bremse.
BR8900543A (pt) Composicao para o beneficiamento de fibras sinteticas,processo para sua preparacao e aplicacao
ES2019600B3 (es) Material de friccion.
DE69408974D1 (de) Verstärkung von chemilumineszenzreaktionen
EP0229107A4 (en) PROTECTIVE HUMAN MONOCLONAL ANTIBODIES TO -i(PSEUDOMONAS AERUGINOSA) EXOTOXIN A.
BR8701478A (pt) Mistura de aclaradores oticos,aplicacao e agente para o aclaramento otico de fibras
DK424789A (da) Instant mousseblanding
NO902162D0 (no) Fremstilling av bituminoes betong omfattende traadstykker.

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: DE ACORDO COM O ART. 37, INDEFIRO DO PRESENTE PEDIDO, UMA VEZ QUE NAO APRESENTA SUFICIENCIA DESCRITIVA (ART. 24 DA LPI); AS REIVINDICACOES ESTAO INDEFINIDAS E/OU NAO ESTAO FUNDAMENTADAS NO RELATORIO DESCRITIVO (ART. 25 DA LPI).

B12B Appeal against refusal [chapter 12.2 patent gazette]
B08L Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 13A, 14A E 15A ANUIDADES.

B08I Publication cancelled [chapter 8.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2256 DE 01/04/2014 POR TER SIDO INDEVIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 13A ATE A 22A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.